AbCellera's ABCL635: Positive Data Fuels Market Optimism and Analyst Upgrades
AbCellera Biologics' positive Phase 2 results for ABCL635 have led to increased analyst confidence and price target adjustments.
Replimune's FDA Approval: A New Chapter for Melanoma Treatment and Investment
Replimune secures FDA accelerated approval for TUDRIQEV, a significant milestone for melanoma treatment and investor interest.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
H&R REIT's C$6.7 Billion Take-Private: A Game Changer for Canadian Real Estate?
H&R REIT's C$6.7 billion acquisition could reshape the Canadian commercial real estate landscape.
Thoma Bravo's C$650M Acquisition of Kneat: What It Means for the Canadian Tech Landscape
Thoma Bravo's C$650M acquisition of Kneat signals a pivotal shift in the Canadian tech market amidst evolving private eq…
PDS Biotech Shifts Focus to PDS0301: Implications for Investors
PDS Biotech's strategic pivot towards PDS0301 raises intriguing questions for investors.
Amneal Pharmaceuticals Strengthens Market Position with Kashiv BioSciences Acquisition
Amneal's acquisition of Kashiv BioSciences positions it as a leader in the biosimilars market, enhancing its R&D and com…
Jazz Pharmaceuticals Expands Pipeline with $1.32 Billion Acquisition of Actio Biosciences
Jazz Pharmaceuticals announces $1.32 billion acquisition of Actio Biosciences, enhancing its rare disease pipeline.
AbCellera Biologics Stock Soars on Positive Phase 2 Trial Results
AbCellera's shares surged 30.3% after positive Phase 2 trial results for its innovative antibody, ABCL635.
Teledyne's $1.1B Deal for Varex Imaging: Analyzing Market Implications
Teledyne's acquisition of Varex Imaging boosts shares and reshapes the medical imaging landscape.
Amneal Pharmaceuticals' Strategic Move: Acquisition of Kashiv BioSciences
Amneal's acquisition of Kashiv BioSciences positions it as a leader in the biosimilars market, indicating potential reve…
Jazz Pharmaceuticals' $1.32B Acquisition: What Investors Need to Know
Jazz Pharmaceuticals is set to acquire Actio Biosciences for $1.32 billion, a move that could reshape its market positio…